A new inhaled treatment for opioid use disorder
A novel inhaled dry powder psychoplastogenic formulation for treating persons with opioid use disorder
This study is testing a new inhaled powder that uses a special compound to help people with opioid use disorder feel better and improve their brain's ability to change, and it's designed for those looking for new ways to manage their addiction.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Quench Medical, INC. NIH-funded |
| Lab location | 1 site (Saint Paul, United States) |
| Project ID | NIH-10916801 on NIH RePORTER |
What this research studies
This research investigates a novel inhaled dry powder formulation aimed at treating opioid use disorder (OUD) by utilizing psychoplastogenic compounds that promote neural plasticity. The approach focuses on the inhalation of a specific compound, 5-MeO-DMT, which has shown potential anti-addictive effects. The study aims to determine the optimal dosing strategy and evaluate the efficacy of this treatment in reducing symptoms associated with OUD. Patients will be monitored for improvements in their condition and overall well-being.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking alternative treatment options.
Not a fit: Patients who are not diagnosed with opioid use disorder or those who have not responded to other treatment modalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with opioid use disorder.
How similar studies have performed: While the use of psychoplastogenic compounds is a relatively novel approach, preliminary evidence suggests potential success in treating similar substance use disorders.
Where this research is happening
Saint Paul, United States
- Quench Medical, INC. — Saint Paul, United States (Active)
Researchers
- Principal investigator: Beverlin Ii, Bryce — Quench Medical, INC.
- Study coordinator: Beverlin Ii, Bryce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.